Volume 364 Number 9435 August 21–27, 2004 The Lancet – London Editorial Articles
637 How complicit are doctors in abuses of detainees?
665 Comparison of lumiracoxib with naproxen and ibuprofen
in the Therapeutic Arthritis Research and Gastrointestinal
Event Trial (TARGET), reduction in ulcer complications
675 Comparison of lumiracoxib with naproxen and ibuprofen
The Lancet – New York
639 A coxib a day won’t keep the doctor away
in the Therapeutic Arthritis Research and Gastrointestinal
641 Statins for all patients with type 2 diabetes: not so soon
Event Trial (TARGET), cardiovascular outcomes
642 Tonsillectomy technique—tradition versus technology
685 Primary prevention of cardiovascular disease with
atorvastatin in type 2 diabetes in the CollaborativeAtorvastatin Diabetes Study (CARDS)
644 Nosocomial bacteraemia caused by Staphylococcus aureus
645 Women undergoing termination of pregnancy should be
697 Tonsillectomy technique as a risk factor for postoperative
screened for gestational trophoblastic neoplasia
haemorrhageNational Prospective Tonsillectomy AuditResearch Letters
703 Risk and outcome of nosocomial Staphylococcus aureus
648 Rabies transmission from organ transplants in the USA
Deputy editor
bacteraemia in nasal carriers versus non-carriers
Executive editors
649 Is repeated caesarean section a consequence of elective
705 Routine terminations of pregnancy—should we screen
World Report Clinical Picture Managing editor Senior editors Perspectives
709 Pathophysiology of airflow limitation in chronic
655 Book: Reclaiming dignity from despair in Alzheimer’s
Rapid Review
722 Pathogenetic mechanisms of parkin in Parkinson’s
North American editor
Michael McCarthy (Seattle)T +1 206 706 7461North American senior editor Health and Human Rights European senior editor
725 Abu Ghraib: its legacy for military medicine
Obituary Case Report Senior assistant editors Correspondence Assistant editors
659 Use of selective serotonin reuptake inhibitors in
childhood depressionT Wohlfarth and others; F Curtin, P Schulz; A J Salerian; C J Whittington and othersEditorial researcher Rachael Davies Editorial assistant C W Baker; J J Segall; J Mann; M L Wahlqvist
663 Outdoor air pollution: the effects of ozone
Web content coordinator Contributing editors Dorothy Bonn
Peer reviewed and fast-tracked to publication in 4 weeks
Information for authors: International Advisory Board Karen Antman (New York)
For personal use. Only reproduce with permission from Elsevi
PUREPAC PHARMACEUTICAL CO., Plaintiff-Appellee, v., 2003 WL 25585736. 2003 WL 25585736 (C.A.D.C.) (Appellate Brief)United States Court of Appeals, District of Columbia Circuit. PUREPAC PHARMACEUTICAL CO., Plaintiff-Appellee,Tommy G. THOMPSON, Secretary of Health and Human Services, and MarkB. McClellan, Commissioner of Food and Drugs, Defendants-Appellees,Torpharm, Inc. and Apotex, Inc., I
Press release For immediate release WATER-JEL, PROFESSIONAL TREATMENT FOR EVERYDAY BURNS, --Widespread use in fire fighting and emergency medical fields for 20 years (Chicago-October, 2002)- Every 25 seconds someone in the United Statesis burned or scalded in their home, according to the American Burn Associationand the Burn Foundation. Burn-Jel and Water-Jel, two hydro-based gel products, h
Volume 364 Number 9435 August 21–27, 2004